| 51 |
22715896 | Vandetanib: in medullary thyroid cancer. | 2012 Jul 9 |
1 |
| 52 |
22898678 | Vandetanib in locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 2 trial. | 2012 Sep |
1 |
| 53 |
20665703 | ZD6474 enhances paclitaxel antiproliferative and apoptotic effects in breast carcinoma cells. | 2011 Feb |
2 |
| 54 |
21247406 | Emerging therapies in the treatment of locally advanced squamous cell cancers of head and neck. | 2011 May |
2 |
| 55 |
21350000 | Vandetanib restores head and neck squamous cell carcinoma cells' sensitivity to cisplatin and radiation in vivo and in vitro. | 2011 Apr 1 |
2 |
| 56 |
21410294 | Pharmacokinetic drug interactions with vandetanib during coadministration with rifampicin or itraconazole. | 2011 |
1 |
| 57 |
21537841 | Vandetanib inhibits both VEGFR-2 and EGFR signalling at clinically relevant drug levels in preclinical models of human cancer. | 2011 Jul |
5 |
| 58 |
21549594 | Radiosynthesis of [11C]Vandetanib and [11C]chloro-Vandetanib as new potential PET agents for imaging of VEGFR in cancer. | 2011 Jun 1 |
4 |
| 59 |
21770481 | Vandetanib: first global approval. | 2011 Jul 9 |
1 |
| 60 |
21819274 | Vandetanib for the treatment of non-small-cell lung cancer. | 2011 Oct |
1 |
| 61 |
21836817 | Vandetanib (ZD6474) in the Treatment of Medullary Thyroid Cancer. | 2011 |
4 |
| 62 |
22346266 | Photosensitivity reactions to vandetanib: redevelopment after sequential treatment with docetaxel. | 2011 Dec |
2 |
| 63 |
22393954 | Efficacy and safety of vandetanib, a dual VEGFR and EGFR inhibitor, in advanced non-small-cell lung cancer: a systematic review and meta-analysis. | 2011 |
1 |
| 64 |
20068097 | Vandetanib, designed to inhibit VEGFR2 and EGFR signaling, had no clinical activity as monotherapy for recurrent ovarian cancer and no detectable modulation of VEGFR2. | 2010 Jan 15 |
1 |
| 65 |
20137866 | Phase I study of vandetanib with radiotherapy and temozolomide for newly diagnosed glioblastoma. | 2010 Sep 1 |
1 |
| 66 |
20139705 | ZD6474, a dual tyrosine kinase inhibitor of EGFR and VEGFR-2, inhibits MAPK/ERK and AKT/PI3-K and induces apoptosis in breast cancer cells. | 2010 Apr 15 |
4 |
| 67 |
20371662 | Vandetanib (100 mg) in patients with locally advanced or metastatic hereditary medullary thyroid cancer. | 2010 Jun |
1 |
| 68 |
20371720 | ZD6474, a multitargeted inhibitor for receptor tyrosine kinases, suppresses growth of gliomas expressing an epidermal growth factor receptor mutant, EGFRvIII, in the brain. | 2010 Apr |
2 |
| 69 |
20570559 | Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. | 2010 Jul |
2 |
| 70 |
20859451 | Current status of vandetanib (ZD6474) in the treatment of non-small cell lung cancer. | 2010 Sep 13 |
4 |
| 71 |
20868411 | Therapeutic hotline. A rare vandetanib-induced photo-allergic drug eruption. | 2010 Sep-Oct |
1 |
| 72 |
20921456 | Phase I study of vandetanib during and after radiotherapy in children with diffuse intrinsic pontine glioma. | 2010 Nov 1 |
1 |
| 73 |
20967300 | Vandetanib: An overview of its clinical development in NSCLC and other tumors. | 2010 Sep |
2 |
| 74 |
19211364 | [Advances in the treatment of thyroid cancer in the era of molecularly targeted therapies]. | 2009 Jan |
1 |
| 75 |
19318229 | Growth inhibition by tyrosine kinase inhibitors in mesothelioma cell lines. | 2009 Jun |
1 |
| 76 |
19319137 | Vandetanib (ZD6474), an inhibitor of VEGFR and EGFR signalling, as a novel molecular-targeted therapy against cholangiocarcinoma. | 2009 Apr 21 |
3 |
| 77 |
19332730 | Vandetanib versus gefitinib in patients with advanced non-small-cell lung cancer: results from a two-part, double-blind, randomized phase ii study. | 2009 May 20 |
3 |
| 78 |
19349511 | Vandetanib (ZD6474), a dual inhibitor of vascular endothelial growth factor receptor (VEGFR) and epidermal growth factor receptor (EGFR) tyrosine kinases: current status and future directions. | 2009 Apr |
5 |
| 79 |
19491268 | Effects of vandetanib on lung adenocarcinoma cells harboring epidermal growth factor receptor T790M mutation in vivo. | 2009 Jun 15 |
3 |
| 80 |
19512898 | Corneal verticillata after dual anti-epidermal growth factor receptor and anti-vascular endothelial growth factor receptor 2 therapy (vandetanib) for anaplastic astrocytoma. | 2009 Jul |
3 |
| 81 |
19946413 | DCE-MRI assessment of the effect of vandetanib on tumor vasculature in patients with advanced colorectal cancer and liver metastases: a randomized phase I study. | 2009 Sep 21 |
1 |
| 82 |
17393165 | Dose scheduling of the dual VEGFR and EGFR tyrosine kinase inhibitor vandetanib (ZD6474, Zactima) in combination with radiotherapy in EGFR-positive and EGFR-null human head and neck tumor xenografts. | 2008 Feb |
6 |
| 83 |
18177496 | Proliferation of Ewing sarcoma cell lines is suppressed by the receptor tyrosine kinase inhibitors gefitinib and vandetanib. | 2008 Jan 4 |
2 |
| 84 |
18347145 | Dual inhibition of VEGFR and EGFR signaling reduces the incidence and size of intestinal adenomas in Apc(Min/+) mice. | 2008 Mar |
2 |
| 85 |
18364248 | Novel dual targeting strategy with vandetanib induces tumor cell apoptosis and inhibits angiogenesis in malignant pleural mesothelioma cells expressing RET oncogenic rearrangement. | 2008 Jun 28 |
2 |
| 86 |
18379357 | A randomized, double-blind, phase IIa dose-finding study of Vandetanib (ZD6474) in Japanese patients with non-small cell lung cancer. | 2008 Apr |
2 |
| 87 |
18687659 | Differential response of primary tumor versus lymphatic metastasis to VEGFR-2 and VEGFR-3 kinase inhibitors cediranib and vandetanib. | 2008 Aug |
1 |
| 88 |
21479415 | Antitumor activity of ZD6474 in a metastatic orthotopic brain tumor model. | 2008 May-Jun |
2 |
| 89 |
17203163 | Antitumor effects of ZD6474 on head and neck squamous cell carcinoma. | 2007 Feb |
3 |
| 90 |
17243944 | Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis. | 2007 Feb |
1 |
| 91 |
17272980 | Combined targeted therapies in non-small cell lung cancer: a winner strategy? | 2007 Mar |
1 |
| 92 |
17308046 | Targeted therapy of orthotopic human lung cancer by combined vascular endothelial growth factor and epidermal growth factor receptor signaling blockade. | 2007 Feb |
3 |
| 93 |
17414626 | Antiangiogenic and antitumor activity of a novel vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor ZD6474 in a metastatic human pancreatic tumor model. | 2007 Jun |
2 |
| 94 |
17631646 | Induction of cell cycle arrest and apoptosis in human nasopharyngeal carcinoma cells by ZD6474, an inhibitor of VEGFR tyrosine kinase with additional activity against EGFR tyrosine kinase. | 2007 Nov 1 |
3 |
| 95 |
17671152 | Vascular endothelial growth factor receptor tyrosine kinase inhibitors vandetanib (ZD6474) and AZD2171 in lung cancer. | 2007 Aug 1 |
2 |
| 96 |
17878479 | Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. | 2007 Sep 20 |
1 |
| 97 |
17889445 | Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. | 2007 Dec 1 |
3 |
| 98 |
16377413 | ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. | 2006 Jan 1 |
1 |
| 99 |
16688779 | Anti-tumor activity of the combination of cetuximab, an anti-EGFR blocking monoclonal antibody and ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinases. | 2006 Aug |
3 |
| 100 |
16783964 | ZD6474, an inhibitor of vascular endothelial growth factor receptor tyrosine kinase, inhibits growth of experimental lung metastasis and production of malignant pleural effusions in a non-small cell lung cancer model. | 2006 |
5 |